Byongen Therapeutics is a China-based, globally-oriented biotech company specializing in original gene delivery innovations. We aim to solve clinical delivery challenges through systematic AAV capsid engineering. Integrating AI, rational design, and directed evolution, our DynEvoLib® platform drives precision evolution of AAV capsids to accelerate high-potential gene therapy clinical translation. We are dedicated to developing precise, safe, and efficient gene therapies that overcome current treatment barriers, delivering transformative clinical value and new hope to patients globally.
Effective and safe delivery vectors are the cornerstone of successful gene therapy. To overcome the bottlenecks of traditional AAV capsid R&D, Byongen Therapeutics has developed the DynEvoLib® platform. This integrated system combines AI-assisted and rational design, automated capture, calibration, and parallel evaluation. By covering the entire workflow from initial design to lead candidate discovery, DynEvoLib® significantly enhances development efficiency and evaluation precision, providing robust technical solutions for gene therapy advancement.
